Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Mol Med. 2011;17(7-8):579-87. doi: 10.2119/molmed.2010.00157. Epub 2011 Mar 11.
Mesenchymal stromal cells (MSCs), also called mesenchymal stem cells, migrate and function as stromal cells in tumor tissues. The effects of MSCs on tumor growth are controversial. In this study, we showed that MSCs increase proliferation of tumor cells in vitro and promote tumor growth in vivo. We also further analyzed the mechanisms that underlie these effects. For use in in vitro and in vivo experiments, we established a bone marrow-derived mesenchymal stromal cell line from cells isolated in C57BL/6 mice. Effects of murine MSCs on tumor cell proliferation in vitro were analyzed in a coculture model with B16-LacZ cells. Both coculture with MSCs and treatment with MSC-conditioned media led to enhanced growth of B16-LacZ cells, although the magnitude of growth stimulation in cocultured cells was greater than that of cells treated with conditioned media. Co-injection of B16-LacZ cells and MSCs into syngeneic mice led to increased tumor size compared with injection of B16-LacZ cells alone. Identical experiments using Lewis lung carcinoma (LLC) cells instead of B16-LacZ cells yielded similar results. Consistent with a role for neovascularization in MSC-mediated tumor growth, tumor vessel area was greater in tumors resulting from co-injection of B16-LacZ cells or LLCs with MSCs than in tumors induced by injection of cancer cells alone. Co-injected MSCs directly supported the tumor vasculature by localizing close to vascular walls and by expressing an endothelial marker. Furthermore, secretion of leukemia inhibitory factor, macrophage colony-stimulating factor, macrophage inflammatory protein-2 and vascular endothelial growth factor was increased in cocultures of MSCs and B16-LacZ cells compared with B16-LacZ cells alone. Together, these results indicate that MSCs promote tumor growth both in vitro and in vivo and suggest that tumor promotion in vivo may be attributable in part to enhanced angiogenesis.
间充质基质细胞(MSCs),也称为间充质干细胞,在肿瘤组织中迁移并作为基质细胞发挥功能。MSCs 对肿瘤生长的影响存在争议。在这项研究中,我们表明 MSCs 可在体外增加肿瘤细胞的增殖,并促进体内肿瘤的生长。我们还进一步分析了这些作用的机制。为了在体内和体外实验中使用,我们从 C57BL/6 小鼠分离的细胞中建立了骨髓来源的间充质基质细胞系。在与 B16-LacZ 细胞共培养的模型中分析了鼠 MSCs 对肿瘤细胞增殖的影响。MSCs 共培养和 MSC 条件培养基处理均导致 B16-LacZ 细胞生长增强,尽管共培养细胞的生长刺激幅度大于用条件培养基处理的细胞。将 B16-LacZ 细胞和 MSCs 共同注射到同基因小鼠中会导致肿瘤大小增加,而单独注射 B16-LacZ 细胞则不会。用 Lewis 肺癌(LLC)细胞代替 B16-LacZ 细胞进行相同的实验也得到了类似的结果。与 MSC 介导的肿瘤生长中的新生血管形成作用一致,与单独注射癌细胞诱导的肿瘤相比,共注射 B16-LacZ 细胞或 LLC 与 MSCs 诱导的肿瘤中的肿瘤血管面积更大。共注射的 MSCs 通过靠近血管壁定位并表达内皮标记物,直接支持肿瘤血管系统。此外,与单独的 B16-LacZ 细胞相比,MSCs 与 B16-LacZ 细胞共培养时,白血病抑制因子、巨噬细胞集落刺激因子、巨噬细胞炎症蛋白-2 和血管内皮生长因子的分泌增加。总之,这些结果表明 MSCs 可在体内和体外促进肿瘤生长,并提示体内肿瘤促进作用部分归因于新生血管形成的增强。